ARCT-810
ARCT-810-02
Phase 2 mab completed
Quick answer
ARCT-810 for Ornithine Transcarbamylase Deficiency is a Phase 2 program (mab) at Arcturus Therapeutics Holdings with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Arcturus Therapeutics Holdings
- Indication
- Ornithine Transcarbamylase Deficiency
- Phase
- Phase 2
- Modality
- mab
- Status
- completed